Payment reform in the United States is moving quickly, but there are still a lot of unknowns among providers. Meetings like the ACO & Emerging Healthcare Delivery Coalition help accountable care organizations (ACOs) and providers share best practices and figure out how to succeed, said Mark McClellan, MD, PhD, director of the Duke-Margolis Center for Health Policy and keynote speaker at the ACO Coalition's fall meeting in Philadelphia, Pennsylvania, October 20-21. Learn more about the meeting and register.
Payment reform in the United States is moving quickly, but there are still a lot of unknowns among providers. Meetings like the ACO & Emerging Healthcare Delivery Coalition help accountable care organizations (ACOs) and providers share best practices and figure out how to succeed, said Mark McClellan, MD, PhD, director of the Duke-Margolis Center for Health Policy and keynote speaker at the ACO Coalition's fall meeting in Philadelphia, Pennsylvania, October 20-21. Learn more about the meeting and register.
Transcript (slightly modified)
Why should someone attend the ACO & Emerging Healthcare Delivery Coalition Fall Live Meeting?
This is a critical time for payment reform and delivery reform in the United States, and in the Medicare program and for Medicare beneficiaries in particular.
We are moving down the road to new payment models—we now have several years of experience with ACOs, growing experience with other types of payment reforms, like bundled episode payments. They are showing some signs of promising results, particularly in improving quality. But we definitely aren't there yet, in terms of healthcare providers around the country knowing the things that they can do right now to have the biggest impact on improving outcomes for their patients, and the biggest impact on getting overall costs down.
And meetings like this one are critical for sharing ideas, for keeping up to date with payment reforms, for figuring out how to succeed in this very challenging world of value-based payment and higher expectations about high-value healthcare delivery.
A meta-analysis showed that control group outcomes in psilocybin trials for depression were significantly weaker than those in selective serotonin reuptake inhibitor (SSRI) and esketamine trials, suggesting that psilocybin’s large observed treatment effects may be inflated by methodological factors such as functional unblinding and expectancy bias.
Read More
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More
Legal Navigation Services Key to Addressing Disparities in Cancer Care
July 31st 2025A significant number of patients with cancer, caregivers, and health care professionals face significant disparities in legal issues, with the most common needs revolving around health insurance, finances, employment, and disability insurance.
Read More